

Contents

Acknowledgments	viii
Foreword	ix
Chapter 1: Introduction to Regulatory Strategy	1
By Darin S. Oppenheimer, Jessica L. Hale, Suraj Ramachandran and George A. Cusatis	
Chapter 2: The Regulatory Team.....	9
By Naseem Kabir, Susan Capps and Grace Jiang	
Chapter 3: Regulatory Intelligence Step 1: Information Collection—A Compilation of Website Addresses	23
By William K. Sietsema, PhD	
Chapter 4: The Elements of Global Regulatory Strategy—the Basics.....	31
By Neal E. Storm	
Chapter 5: Assembling and Utilizing Target Product Profiles.....	45
By Anastassios Retzios, PhD	
Chapter 6: Preclinical Safety Guidelines Supporting International Drug Registration	57
By John C. Kapeghian, PhD, DABT	
Chapter 7: CMC Regulatory Strategy	79
By Stephen Antonelli and Michael Craig	
Chapter 8: Strategies for Clinical Development Planning.....	89
By William Sietsema, PhD and Eric Brass, MD, PhD	
Chapter 9: Clinical Trial Application Planning.....	99
By Sharry Arora	
Chapter 10: Global Orphan Drug Regulations	107
By Jocelyn Jennings, MS, RAC	
Chapter 11: Pediatric Strategies.....	117
By Klaus Rose, MD, MS	
Chapter 12: So Your Drug has a Friend? Companion Diagnostic Codevelopment Strategies.....	133
By Catherine Lofton-Day, Dave Kern and Mya Thomae	
Chapter 13: Interacting With Regulators	145
By Eric Brass, MD, PhD and William Sietsema, PhD	
Chapter 14: Regulatory Pathways.....	155
By Pallavi Trivedi, MPH, RAC	
Chapter 15: Global Regulatory Strategy.....	187
By Chris Walker and Tina Soulis	
Chapter 16: Preparing for an FDA Advisory Committee: High Risk, High Reward.....	205
By Michael J. Vivion	
Chapter 17: Considerations for Healthcare Products' Lifecycle Management	221
By Timothy Pang	
Chapter 18: Medical Writing Strategies: Aligning Regulatory Documents with Strategic Goals.....	235
By Kathy Wekselman	
Index	243

Case Studies

Case Study 8-1. Teduglutide and the Selection of a Clinically Meaningful Endpoint.....	94
Case Study 8-2. Adverse Events of Special Interest.....	95
Case Study 8-3. Excluding Unacceptable Risk.....	96
Case Study 13-1. Vascepa for the Treatment of Hypertriglyceridemia.....	151

Figures

Figure 5-1. Target Product Profile (TPP) Planning Process.....	45
Figure 5-2. Target Product Profile.....	48
Figure 8-1. Clinical Development Program Reverse-Engineering Principle.....	90
Figure 8-2. Sample Timeline With one Option for Displaying High-Level Information on Program Timing.....	92
Figure 10-1. Sponsor’s Guide to an Orphan Designation.....	109
Figure 14-1. EMA Centralised Procedure Flowchart With Major Milestones.....	163
Figure 14-2. Flow Chart of Drug and Device Review in Japan.....	167
Figure 14-3 Japan’s New Approval System for Commercialization of Cellular Therapy Products.....	169
Figure 14-4. Standard Registration Process with TGA.....	173
Figure 14-5. TGA Priority Registration Process Diagram.....	175
Figure 14-6. TGA Provisional Registration Process Diagram.....	177
Figure 14-7. TGA Regulation of Biologicals.....	179
Figure 15-1. Multidisciplinary Product Development.....	188
Figure 15-2. Key Interactions Between Marketing and Regulatory.....	190
Figure 15-3. Clinical Development Strategy in Asia.....	194
Figure 15-4. The CTD Triangle.....	195
Figure 15-5. Global Technology System for Safety Monitoring.....	199
Figure 16-1. Typical Advisory Committee Meeting Seating Arrangement.....	206

Tables

Table 3-1. Sources of Regulatory Intelligence.....	23
Table 3-2. Websites for Healthcare Product Regulations by Region.....	24
Table 3-3. Regulatory Intelligence Databases.....	26
Table 3-4. Professional Associations for Regulatory Professionals.....	26
Table 3-5. Clinical Trial Databases.....	27
Table 3-6. Examples of Web Pages for Subscribing to Regulatory Updates.....	28
Table 3-7. Regulatory Agency Twitter Handles.....	28
Table 4-1. Key Global Regulatory Plan Elements.....	32
Table 4-2. Changes a Global Regulatory Plan Should Anticipate, Mitigate or Manage.....	32
Table 4-3. Regulatory Intelligence Tool Examples to Understand the Competitive Product Landscape.....	39
Table 4-4. Regulatory Journals for Understanding Shifting Regulatory Policy.....	40
Table 4-5. Global Regulatory Plan Components—Sample Table of Contents.....	43
Table 5-1. Introductory/Top Table Presenting Certain Drug Key Elements.....	50

Table 5-2. TPP Panel for the Clinical use and Efficacy attributes (mainly the primary endpoint) of a Liquid Immunoglobulin G Preparation in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	51
Table 5-3. TPP Panel Summarizing the Safety Information a Liquid Immunoglobulin G Preparation in the Treatment of Primary Immunodeficiency	52
Table 5-4. Specific Areas to be Covered by the TPP Asset Characterization Module	54
Table 6-1. Recommended Duration of Repeat-Dose Toxicity Studies to Support the Conduct of Clinical Trials	71
Table 7-1. Centralised Procedure Requirements Based on Product Type.....	81
Table 7-2. Regulatory Authorities by Country.....	81
Table 8-1. Study Outline Document Template.....	91
Table 10-1. Countries With Orphan Drug Regulations and Population Prevalence.....	110
Table 10-2. Overview of Orphan Drug Designation Incentives	111
Table 10-3. Global Health Authority Orphan Drug Office.....	113
Table 10-4. Orphan Drug Regulations by Country	114
Table 10-5. Orphan Drug Templates and Submission Tips.....	114
Table 13-1. Communication Objectives for Sponsor-Regulator Interactions	146
Table 13-2. Examples of Open vs. Content-Specific Questions to Regulators.....	147
Table 13-3. Summary of Regulatory Agency Meeting Types	152
Table 14-1. US Pathways and Exclusivity	156
Table 14-2. FDA Drug and Biologic NDA Application Review Timeframes	156
Table 14-3. FDA Programs to Expedite Approval of Drug/Biologic Products Intended to Treat Serious Conditions	160
Table 14-4. EU Application Procedures for Drugs and Biologics	162
Table 14-5. EU Standard Timelines for Centralised Applications	162
Table 14-6. EU Standard Mutual Recognition Procedure Timelines	163
Table 14-7. EU Standard Decentralised Procedure Timelines	164
Table 14-8. Drug MAA Types in EU.....	165
Table 14-9. EU Mechanisms for Accelerated Drug and Biologics Development and Approval.....	166
Table 14-10. Japan Drug Filing Fees.....	168
Table 14-11. Human Drug (Pharmaceutical and Biological) Submission and Application Review Timeframe and Fees as of April 1, 2019	171
Table 14-12. TGA Application and Evaluation Fees in Australian Dollars for Prescription Medicines as of December 2019.....	178
Table 14-13. Overview of the TGA Application Process and Timeframes	180
Table 14-14. TGA Fees in Australia Dollars for Sponsoring Biologicals	180
Table 15-1. Comparison of Regulatory and HTA Requirements	191
Table 15-2. Overview of Specific Country Requirements	197
Table 17-1. CM Considerations by Phase of Product Lifecycle.....	223
Table 17-2. Lifecycle Evolution of Oral Antidiabetic Drugs in the US and EU	227
Table 17-3. Remicade US Indication Expansion in the First Five Years After Launch	228
Table 18-1. Examples of Structured Regulatory Goals	238
Table 18-2. Best Practice Examples for Clear Regulatory Writing.....	241